Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, Europe, and internationally. More Details
Adequate balance sheet with limited growth.
Share Price & News
How has Yourgene Health's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: YGEN is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: YGEN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
7 Day Return
GB Medical Equipment
1 Year Return
GB Medical Equipment
Return vs Industry: YGEN underperformed the UK Medical Equipment industry which returned 2.2% over the past year.
Return vs Market: YGEN underperformed the UK Market which returned 25.5% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Yourgene Health's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StWhat You Need To Know About Yourgene Health Plc's (LON:YGEN) Investor Composition
2 months ago | Simply Wall StDoes This Valuation Of Yourgene Health Plc (LON:YGEN) Imply Investors Are Overpaying?
3 months ago | Simply Wall StWhat Did Yourgene Health's (LON:YGEN) CEO Take Home Last Year?
Is Yourgene Health undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: YGEN (£0.14) is trading above our estimate of fair value (£0.13)
Significantly Below Fair Value: YGEN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: YGEN is unprofitable, so we can't compare its PE Ratio to the GB Medical Equipment industry average.
PE vs Market: YGEN is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate YGEN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: YGEN is good value based on its PB Ratio (2.2x) compared to the GB Medical Equipment industry average (3.7x).
How is Yourgene Health forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: YGEN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: YGEN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: YGEN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: YGEN's revenue (21.2% per year) is forecast to grow faster than the UK market (5.3% per year).
High Growth Revenue: YGEN's revenue (21.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if YGEN's Return on Equity is forecast to be high in 3 years time
How has Yourgene Health performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: YGEN is currently unprofitable.
Growing Profit Margin: YGEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: YGEN is unprofitable, but has reduced losses over the past 5 years at a rate of 38.8% per year.
Accelerating Growth: Unable to compare YGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: YGEN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (13.8%).
Return on Equity
High ROE: YGEN has a negative Return on Equity (-8.48%), as it is currently unprofitable.
How is Yourgene Health's financial position?
Financial Position Analysis
Short Term Liabilities: YGEN's short term assets (£20.2M) exceed its short term liabilities (£9.1M).
Long Term Liabilities: YGEN's short term assets (£20.2M) exceed its long term liabilities (£7.3M).
Debt to Equity History and Analysis
Debt Level: YGEN's debt to equity ratio (0.7%) is considered satisfactory.
Reducing Debt: YGEN's debt to equity ratio has increased from 0.2% to 0.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: YGEN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if YGEN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Yourgene Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate YGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate YGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if YGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if YGEN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of YGEN's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Lyn Rees (46 yo)
Mr. Lyn Dafydd Rees serves as Non-Executive Director at MyHealthChecked Plc (formerly known as Concepta PLC) since November 2019. Mr. Rees serves as Chief Executive Officer at Yourgene Health PLC and holds...
CEO Compensation Analysis
Compensation vs Market: Lyn's total compensation ($USD304.99K) is about average for companies of similar size in the UK market ($USD338.34K).
Compensation vs Earnings: Lyn's compensation has increased whilst the company is unprofitable.
Experienced Management: YGEN's management team is considered experienced (2.6 years average tenure).
Experienced Board: YGEN's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: YGEN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.3%.
Yourgene Health Plc's company bio, employee growth, exchange listings and data sources
- Name: Yourgene Health Plc
- Ticker: YGEN
- Exchange: AIM
- Founded: 2000
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: UK£102.046m
- Shares outstanding: 723.06m
- Website: https://www.yourgene-health.com
Number of Employees
- Yourgene Health Plc
- Citylabs 1.0
- Nelson Street
- Greater Manchester
- M13 9NQ
- United Kingdom
Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, Europe, and inter...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/07 19:35|
|End of Day Share Price||2021/05/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.